Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KURA ONCOLOGY, INC.

(KURA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kura Oncology : to Participate in Two Upcoming Investor Conferences

09/07/2021 | 07:30am EDT

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences:

  • A pre-recorded presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand beginning at 7:00 a.m. ET / 4:00 a.m. PT on September 13, 2021; and

  • A pre-recorded fireside chat at the Cantor Global Healthcare Conference, available at 3:20 p.m. ET / 12:20 p.m. PT on September 27, 2021.

Audio webcasts of the H.C. Wainwright and Cantor events will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets of patients, including those who have HRAS- and/or PIK3CA-dependent HNSCC. The Company is also developing KO-2806, a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com


Primary Logo

Source: Kura Oncology, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about KURA ONCOLOGY, INC.
10/19KURA ONCOLOGY : Appoints Teresa Bair as Chief Legal Officer
AQ
10/18KURA ONCOLOGY : Appoints Teresa Bair as Chief Legal Officer
GL
10/18Kura Oncology, Inc. Appoints Teresa Bair as Chief Legal Officer
CI
09/13KURA ONCOLOGY : Corporate Presentation - September 2021
PU
09/07KURA ONCOLOGY : to Participate in Two Upcoming Investor Conferences
AQ
08/06KURA ONCOLOGY : Credit Suisse Lowers Kura Oncology's PT to $40 from $42, Updates Model wit..
MT
08/05KURA ONCOLOGY : Q2 Earnings Snapshot
AQ
08/05KURA ONCOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
08/05KURA ONCOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements ..
AQ
08/05Kura Oncology, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -138 M - -
Net cash 2021 497 M - -
P/E ratio 2021 -8,43x
Yield 2021 -
Capitalization 1 164 M 1 164 M -
EV / Sales 2021 -
EV / Sales 2022 339x
Nbr of Employees 111
Free-Float 94,4%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 17,56 $
Average target price 44,57 $
Spread / Average Target 154%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President & Chief Executive Officer
Marc Edward Grasso Chief Financial & Business Officer
Mollie Leoni Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.-46.23%1 164
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610